Regulatory considerations in vaccine design

Area of Science:

• Biotechnology
• Regulatory Science
• Immunology

Background:

• Vaccines are regulated as biologics in the United States.
• The Center for Biologics Evaluation and Research (CBER) oversees vaccine regulation.
• General requirements for safety, purity, and potency (efficacy) must be met.

Purpose of the Study:

• To outline the regulatory framework for vaccine approval in the US.
• To detail the requirements for demonstrating vaccine efficacy.
• To explain the process of obtaining approval for clinical trials and marketing.

Main Methods:

• Vaccine efficacy is demonstrated through Phase III clinical trials.
• Well-controlled, double-blind, placebo-controlled trials are often sufficient for licensing.
• Investigational New Drug (IND) applications are used for clinical trial approval.
• Product License Applications (PLA) and Establishment License Applications (ELA) are used for marketing approval.

Main Results:

• Specific standards for each vaccine are determined by the manufacturer and CBER.
• Efficacy data can come from US or international studies, with bridging studies potentially needed.
• Postmarketing Phase IV trials are used to gather large-scale safety data.

Conclusions:

• Clear communication with the Food and Drug Administration (FDA) is crucial for efficient vaccine development and approval.
• Meeting regulatory requirements ensures vaccine safety, purity, and potency.
• The regulatory process involves distinct stages from clinical trials to postmarketing surveillance.